Stryker reports Inari disruption: what it means for NARI stock

Published on 10/01/2026 at 19:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker disclosed an Inari backorder in its second-quarter 2026 report. NARI stock reflects the USD 4.90 billion acquisition by Stryker in February 2025.

NARI, US45332Y1091, Illustration mit AI erstellt.

Stryker reported a persistent supply disruption in the Inari Medical business after its second-quarter 2026 results. The issue created a meaningful backorder situation with lost sales, and Stryker's September 8, 2026 conference update said the problem could continue into the fourth quarter, according to GlobeNewswire.

Supply problems reached Inari

Stryker said on July 30, 2026 that supply disruptions in its Peripheral Vascular unit had produced a meaningful backorder and lost sales during the second quarter. Chief executive Kevin Lobo described the backorder as specific to one plant in the Inari business, while management expected conditions to become manageable by the end of the third quarter, the release said.

The later update changed the timing. At the Wells Fargo Healthcare Conference on September 8, 2026, Stryker chief financial officer Preston Wells said the disruption was limiting inventory at customers and new business, with effects expected to continue into the fourth quarter, according to MedTech Dive.

Acquisition value sets the frame

Stryker acquired Inari Medical in February 2025 for about USD 4.90 billion, bringing mechanical thrombectomy systems for blood-clot treatment into its Peripheral Vascular business. The integration of Inari's manufacturing facility became a central operational issue after a cyberattack disrupted manufacturing and shipping, MedTech Dive reported on September 10, 2026.

For the combined company, the supply problem matters because it affects both existing customer inventory and the ability to win new accounts. Stryker shares fell 9.70 percent between September 8 and September 9, 2026, according to MedTech Dive, connecting the Inari disruption to a measurable market reaction in the acquiring company.

Legal overhang also shifts

A New York federal judge dismissed an investor class action on September 23, 2026 that alleged Inari's share price fell after disclosure of a federal anti-kickback investigation. Law360 reported that the judge found the allegations did not plausibly show that Inari paid unlawful kickbacks.

Inari Medical's market frame

The former NARI listing now belongs in the Stryker operating story rather than as a standalone earnings case. The decisive figures are the USD 4.90 billion purchase price, the second-quarter 2026 backorder and the expected continuation of supply effects into the fourth quarter.